Could a popular weight loss drug help beat rectal cancer?
NCT ID NCT07314528
Summary
This study is testing if adding a weight loss medication (a GLP-1 receptor agonist like semaglutide) to standard pre-surgery cancer treatment improves results for overweight patients with locally advanced rectal cancer. Researchers will compare two groups: one gets the standard treatment plus the weight loss drug, and the other gets the standard treatment alone. They want to see if the drug helps patients lose weight, improves how well the cancer responds to treatment, and reduces the chance of the cancer coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER PATIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.